A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Clinical trial NCT07545460 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07545460
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-01
- Primary completion
- 2028-12-01
- Enrollment
- 404
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.